To further assess potential on-target, off-tumor effects, we analyzed CD155 expression patterns alongside reference genes (EGFR, ERBB2, and ROR1), which are currently being investigated in clinical trials for CAR-T therapies (9). The gene discussed is ERBB2; the disease is neoplasm.